文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

游离血红蛋白与触珠蛋白作为ARDS行静脉-静脉ECMO治疗患者预后标志物的潜力

Potential of cell-free hemoglobin and haptoglobin as prognostic markers in patients with ARDS and treatment with veno-venous ECMO.
PubMed 文献 · J Intensive Care · 2023-04-20
一句话结论在ARDS行静脉-静脉ECMO患者中,平均游离血红蛋白>11 mg/dl及平均触珠蛋白≤0.39 g/l与ICU死亡率显著升高独立相关。

该研究纳入2007年1月至2018年12月期间在一家三级ARDS转诊中心接受静脉-静脉ECMO治疗的ARDS患者442例,计算平均游离血红蛋白(mCFH)和平均触珠蛋白(mHp)血浆浓度的截断值,将队列分为ICU死亡率显著不同的组,并进行多因素logistic回归分析。结果显示,mCFH>11 mg/dl组ICU死亡率为70%,显著高于mCFH≤11 mg/dl组的38%(p<0.001);mHp≤0.39 g/l组ICU死亡率为68.7%,显著高于mHp>0.39 g/l组的38.7%(p<0.001)。logistic回归证实CFH分组(OR 3.77)和Hp分组(OR 0.29)与ICU死亡率独立相关。此外,CFH>11 mg/dl的治疗天数比例>13.3%以及Hp≤0.39 g/l的治疗天数比例>18.2%均与ICU死亡率显著升高相关。结论提示,中度溶血(mCFH低至11 mg/dl)即影响接受静脉-静脉ECMO治疗的ARDS患者的死亡率,且应考虑累积剂量效应。

要点

  • 在ARDS行静脉-静脉ECMO患者中,平均游离血红蛋白>11 mg/dl与ICU死亡率显著升高相关(70% vs 38%,p<0.001)。
  • 平均触珠蛋白≤0.39 g/l与ICU死亡率显著升高相关(68.7% vs 38.7%,p<0.001)。
  • 调整混杂因素后,CFH分组与ICU死亡率独立相关(OR 3.77,95%CI 2.51-5.72,p<0.001),Hp分组亦独立相关(OR 0.29,95%CI 0.19-0.43,p<0.001)。
  • CFH>11 mg/dl的治疗天数比例>13.3%时ICU死亡率显著升高(62% vs 33%,p<0.001)。
  • Hp≤0.39 g/l的治疗天数比例>18.2%时ICU死亡率显著升高(60% vs 27%,p<0.001)。

适用人群与场景

  • 2007年1月至2018年12月期间入住一家三级ARDS转诊中心、接受静脉-静脉ECMO治疗的ARDS患者(n=442)。

诊断标准与关键阈值

  • 平均游离血红蛋白(mCFH)截断值11 mg/dl:mCFH≤11 mg/dl组ICU死亡率38%(95%CI 32.22-43.93,n=277),mCFH>11 mg/dl组ICU死亡率70%(95%CI 61.99-76.47,n=165),p<0.001。
  • 平均触珠蛋白(mHp)截断值0.39 g/l:mHp≤0.39 g/l组ICU死亡率68.7%(95%CI 60.91-75.61,n=163),mHp>0.39 g/l组ICU死亡率38.7%(95%CI 33.01-44.72,n=279),p<0.001。
  • CFH>11 mg/dl的治疗天数比例截断值13.3%:≤13.3%组ICU死亡率33%(95%CI 26.81-40.54,n=192),>13.3%组ICU死亡率62%(95%CI 56.05-68.36,n=250),p<0.001。
  • Hp≤0.39 g/l的治疗天数比例截断值18.2%:≤18.2%组ICU死亡率27%(95%CI 19.80-35.14,n=138),>18.2%组ICU死亡率60%(95%CI 54.43-65.70,n=304),p<0.001。

研究设计与关键结果

  • 研究类型为在三级ARDS转诊中心进行的队列研究,纳入2007年1月至2018年12月接受静脉-静脉ECMO治疗的ARDS患者442例。
  • 主要终点为ICU死亡率;mCFH>11 mg/dl组ICU死亡率为70%,显著高于mCFH≤11 mg/dl组的38%(p<0.001)。
  • mHp≤0.39 g/l组ICU死亡率为68.7%,显著高于mHp>0.39 g/l组的38.7%(p<0.001)。
  • 多因素logistic回归(逐步后退法)调整混杂因素后,CFH分组与ICU死亡率独立相关(OR 3.77,95%CI 2.51-5.72,p<0.001);Hp分组亦独立相关(OR 0.29,95%CI 0.19-0.43,p<0.001)。
  • CFH>11 mg/dl的治疗天数比例>13.3%组ICU死亡率为62%,显著高于≤13.3%组的33%(p<0.001)。
  • Hp≤0.39 g/l的治疗天数比例>18.2%组ICU死亡率为60%,显著高于≤18.2%组的27%(p<0.001)。

证据类型、等级与局限

  • 证据类型:队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,对于接受静脉-静脉ECMO治疗的ARDS患者,中度溶血(mCFH水平低至11 mg/dl)即影响死亡率。
  • 作者认为,应考虑CFH>11 mg/dl的相对治疗天数所指示的累积剂量效应。
  • 作者认为,在评估CFH升高带来的损伤效应时,也需要考虑触珠蛋白血浆浓度。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Hemolysis is associated with increased mortality in patients with sepsis, ARDS, or therapy with extracorporeal membrane oxygenation (ECMO). To quantify a critical threshold of hemolysis in patients with ARDS and treatment with veno-venous ECMO, we aimed to identify cutoff values for cell-free hemoglobin (CFH) and haptoglobin (Hp) plasma concentrations associated with a significant increase in ICU mortality.

METHODS: Patients with ARDS admitted to a tertiary ARDS referral center between 01/2007 and 12/2018 and treatment with veno-venous ECMO were included. Cutoff values for mean CFH (mCFH) and mean Hp (mHp) plasma concentrations dividing the cohort into groups with significantly different ICU mortalities were calculated and patient characteristics were compared. A multiple logistic regression model with stepwise backward variable selection was included. In addition, cutoff values for vulnerable relative timespans for the respective CFH and Hp concentrations were calculated.

RESULTS: A quantitative cutoff value of 11 mg/dl for mCFH separated the cohort (n = 442) regarding ICU mortality (mCFH ≤ 11 mg/dl: 38%, [95%-CI: 32.22-43.93] (n = 277) vs. mCFH > 11 mg/dl: 70%, [61.99-76.47] (n = 165), p < 0.001). Analogously, a mHp cutoff value ≤ 0.39 g/l was associated with a significant increase in ICU mortality (mHp ≤ 0.39 g/l: 68.7%, [60.91-75.61] (n = 163) vs. mHp > 0.39 g/l: 38.7%, [33.01-44.72] (n = 279), p < 0.001). The independent association of ICU mortality with CFH and Hp cutoff values was confirmed by logistic regression adjusting for confounders (CFH Grouping: OR 3.77, [2.51-5.72], p < 0.001; Hp Grouping: OR 0.29, [0.19-0.43], p < 0.001). A significant increase in ICU mortality was observed when CFH plasma concentration exceeded the limit of 11 mg/dl on 13.3% of therapy days (≤ 13.3% of days with CFH > 11 mg/dl: 33%; [26.81-40.54] (n = 192) vs. > 13.3% of days with CFH > 11 mg/dl: 62%; [56.05-68.36] (n = 250), p < 0.001). Analogously, a mortality increase was detected when Hp plasma concentration remained ≤ 0.39 g/l for > 18.2% of therapy days (≤ 18.2% days with Hp ≤ 0.39 g/l: 27%; [19.80-35.14] (n = 138) vs. > 18.2% days with Hp ≤ 0.39 g/l: 60%; [54.43-65.70] (n = 304), p < 0.001).

CONCLUSIONS: Moderate hemolysis with mCFH-levels as low as 11 mg/dl impacts mortality in patients with ARDS and therapy with veno-venous ECMO. Furthermore, a cumulative dose effect should be considered indicated by the relative therapy days with CFH-concentrations > 11 mg/dl. In addition, also Hp plasma concentrations need consideration when the injurious effect of elevated CFH is evaluated.

来源:J Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Bünger V, Hunsicker O, Krannich A, et al. Potential of cell-free hemoglobin and haptoglobin as prognostic markers in patients with ARDS and treatment with veno-venous ECMO. J Intensive Care. 2023. PMID: 37081577. doi:10.1186/s40560-023-00664-5

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。